The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 3 briefings matching “diabetes”

Reset all filters

Pharmacology

Pharmacology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

PHARMACOLOGY · PRECLINICAL

Electric Implant: Novel Glucose Control and Weight Loss for Type 2 Diabetes

An electronic implant effectively lowered blood sugar and promoted weight loss in diabetic mice by converting excess glucose for urinary excretion. This breakthrough offers a potential new paradigm for type 2 diabetes management, particularly for patients who struggle with current insulin or drug regimens.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

PHARMACOLOGY · REAL-WORLD COHORT

Intensive Lifestyle Reverses Type 2 Diabetes in Younger Adults

Lifestyle intervention combining diet and exercise can induce type 2 diabetes remission in over half of younger adults, presenting a powerful alternative to lifelong medication. This breakthrough highlights a potent non-pharmacological pathway to potentially reverse type 2 diabetes, especially in younger populations.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

PHARMACOLOGY · RANDOMIZED CLINICAL TRIAL

Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND

In this study, long-term all-cause risk of death in patients with high-risk chronic coronary disease was not significantly different after routine invasive vs initial conservative management. In this long-term follow-up study of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), an international trial of patients with chronic coronary disease, moderate or severe ischemia, left ventricular ejection fraction of 35% or more, and no left main coronary artery disease, unacceptable angina, or recent acute coronary syndrome, participants were randomized at 320 sites in 37 countries beginning August 2012 and followed up through December 2025.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMANov 7, 2026

Interactive Fact Check